Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006529 | 0.84 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2TSHRCYP1A2CYP2D6 | |
| SCHEMBL1009644 | 0.83 | CYP1A2 (0.46) | LMNASMN1; SMN2TSHRCYP1A2CYP2D6 | |
| SCHEMBL1005501 | 0.82 | LMNA (0.45) | PARP1LMNASMN1; SMN2TSHRCYP1A2 | |
| SCHEMBL1007814 | 0.81 | LMNA (0.50) | LMNASMN1; SMN2KMT2ATSHRMEN1 | |
| SCHEMBL1008168 | 0.81 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL1009744 | 0.81 | MAPT (0.52) | LMNATSHRCYP1A2CYP2C19MAPT | |
| SCHEMBL1006846 | 0.81 | SMN1; SMN2 (0.48) | LMNASMN1; SMN2KMT2ATSHRMEN1 | |
| SCHEMBL1894160 | 0.80 | RAB9A (0.49) | LMNASMN1; SMN2KMT2ATSHRMEN1 | |
| SCHEMBL1006791 | 0.80 | LMNA (0.55) | LMNASMN1; SMN2TSHRMAPTALDH1A1 | |
| SCHEMBL1007262 | 0.80 | KMT2A (0.44) | LMNASMN1; SMN2KMT2ATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | claimed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | claimed |
| EP-3169325-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2017-05-24 | — | — | EP | claimed |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | claimed |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2016-07-14 | — | — | US | claimed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | claimed |
| US-11021463-B2 | Therapeutic inhibitory compounds | ATTUNE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3169325-B1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS INC (US) | 2021-04-28 | — | — | EP | disclosed |
| CN-107072985-B | Therapeutic inhibiting compounds | 莱福斯希医药公司 | 2020-02-07 | — | — | CN | disclosed |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10308637-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-06-04 | — | — | US | disclosed |
| US-10266515-B2 | Therapeutic inhibitory compounds | LIFESCI PHARMACEUTICALS, INC. (BB) | 2019-04-23 | — | — | US | disclosed |
| WO-2016011209-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2016-01-21 | — | — | WO | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| EP-2269990-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-01-05 | — | — | EP | disclosed |
| WO-2009119088-A1 | HETEROCYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308637-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | PARP1 1139/4885LMNA 2032/4885SMN1; SMN2 4577/4885 |
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | PARP1 1139/4885LMNA 2032/4885SMN1; SMN2 4577/4885 |
| US-20200031800-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | PARP1 1139/4885LMNA 2032/4885SMN1; SMN2 4577/4885 |
| US-20200031799-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | PARP1 1139/4885LMNA 2032/4885SMN1; SMN2 4577/4885 |
| US-20110118236-A1 | HETEROCYCLIC COMPOUND | GRIN1, GRM1, GRIK1 | PARP1 1561/4885LMNA 4015/4885SMN1; SMN2 3616/4885 |
| US-20160200704-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | PARP1 1139/4885LMNA 2032/4885SMN1; SMN2 4577/4885 |
| US-10266515-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | PARP1 1139/4885LMNA 2032/4885SMN1; SMN2 4577/4885 |
| US-11021463-B2 | Therapeutic inhibitory compounds | KLKB1, SERPINB1, SERPINE1 | PARP1 1139/4885LMNA 2032/4885SMN1; SMN2 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.